Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera (PCV) is a condition characterized by an increased number of red blood cells in the bloodstream. Affected people may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. People with PCV have an increased risk of deep vein thrombosis which can cause a pulmonary embolism; heart attack; and stroke. Most cases are not inherited and are acquired during a person's lifetime. In rare cases, the risk for PCV runs in families and may be inherited in an autosomal dominant manner. The condition has been associated with mutations in the JAK2 and TET2 genes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 297 free, full-text research articles on human participants. First 3 results:

A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
 

Author(s): Christen L Andersen, Nana B Mortensen, Tobias W Klausen, Hanne Vestergaard, Ole W Bjerrum, Hans C Hasselbalch

Journal: Haematologica. 2014 Jan;99(1):e5-7.

 

Last Updated: 15 Jan 2014

Go To URL
Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
 

Author(s): Toshikage Nagao, Tetsuya Kurosu, Yoshihiro Umezawa, Ayako Nogami, Gaku Oshikawa, Shuji Tohda, Masahide Yamamoto, Osamu Miura

Journal:

 

The gain of function mutation JAK2-V617F is very frequently found in myeloproliferative neoplasms (MPNs) and is strongly implicated in pathogenesis of these and other hematological malignancies. Here we report establishment of a new leukemia cell line, PVTL-1, homozygous for JAK2-V617F ...

Last Updated: 9 Jan 2014

Go To URL
Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera.
 

Author(s): Miguel Gallardo, Santiago Barrio, Marisol Fernandez, Alberto Paradela, Alicia Arenas, Oscar Toldos, Rosa Ayala, Enriqueta Albizua, Ana Jimenez, Santiago Redondo, Rosa Maria Garcia-Martin, Florinda Gilsanz, Juan Pablo Albar, Joaquin Martinez-Lopez

Journal:

 

JAK-STAT signaling through the JAK2V617F mutation is central to the pathogenesis of myeloproliferative neoplasms (MPN). However, other events could precede the JAK2 mutation. The aim of this study is to analyze the phenotypic divergence between polycytemia vera (PV) and essential ...

Last Updated: 29 Nov 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 18 free, full-text review articles on human participants. First 3 results:

Neutrophilic dermatosis of the dorsal hands in a patient with polycythemia vera.
 

Author(s): Pedro de Vasconcelos, Luís Soares-Almeida, Paulo Filipe

Journal: Acta Dermatovenerol Alp Pannonica Adriat. 2013 ;22(2):53-4.

 

Last Updated: 9 Jul 2013

Go To URL
[Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
 

Author(s): Megumi Funakoshi-Tago

Journal: Yakugaku Zasshi. 2011 ;131(8):1183-7.

 

It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) ...

Last Updated: 1 Aug 2011

Go To URL
Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera.
 

Author(s): Claire Harrison

Journal: Hematology Am Soc Hematol Educ Program. 2010 ;2010():129-34.

 

The seminal discovery of the JAK2V617F mutation, which is highly prevalent in Philadelphia-negative myeloproliferative disorders, now renamed neoplasms, triggered an almost unprecedented explosion of interest and data in the field. Descriptions of additional mutations in exon 12 of ...

Last Updated: 17 Jan 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: Polycythemia Vera; Essential Thrombocythemia

 

Last Updated: 4 Sep 2014

Go to URL
AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
 

Status: Not yet recruiting

Condition Summary: Polycythemia Vera

 

Last Updated: 14 Aug 2014

Go to URL

Last Updated: 29 Aug 2014

Go to URL